Loxapinum [Inn-Latin] en es it fr

Loxapinum [Inn-Latin] Brand names, Loxapinum [Inn-Latin] Analogs

Loxapinum [Inn-Latin] Brand Names Mixture

  • No information avaliable

Loxapinum [Inn-Latin] Chemical_Formula


Loxapinum [Inn-Latin] RX_link


Loxapinum [Inn-Latin] fda sheet

Loxapinum [Inn-Latin] msds (material safety sheet)

Loxapinum [Inn-Latin] Synthesis Reference

Neth. pat. Appl. 6,406,089 corresp to Schmutz et al., U.S. pat. 3,546,226 (1964, 1970 both to Wander)

Loxapinum [Inn-Latin] Molecular Weight

327.808 g/mol

Loxapinum [Inn-Latin] Melting Point

109-110 oC

Loxapinum [Inn-Latin] H2O Solubility

No information avaliable

Loxapinum [Inn-Latin] State


Loxapinum [Inn-Latin] LogP


Loxapinum [Inn-Latin] Dosage Forms

Tablet; Capsule; Oral solution; IV solution; IM solution

Loxapinum [Inn-Latin] Indication

For the management of the manifestations of psychotic disorders

Loxapinum [Inn-Latin] Pharmacology

Loxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Pharmacologically, Loxapine is a tranquilizer for which the exact mode of action has not been established.

Loxapinum [Inn-Latin] Absorption

Systemic bioavailability of the parent drug was only about one third that after an equivalent intramuscular dose (25 mg base) in male volunteers

Loxapinum [Inn-Latin] side effects and Toxicity

LD50=65 mg/kg (Orally in mice)

Loxapinum [Inn-Latin] Patient Information

Loxapinum [Inn-Latin] Organisms Affected

Humans and other mammals